Glycan biology, sugar molecules as aging biomarkers.

Summary

Aging is characterized by a systemic shift in the immunoglobulin G (IgG) glycome toward a pro-inflammatory profile, primarily defined by a significant decline in terminal galactosylation and sialylation and an increase in agalactosylated (G0) structures (Direct, High; PMID: 24325898, PMID: 39126246). Glycan-based aging clocks, such as GlycanAge, demonstrate superior predictive power for chronological and biological age compared to traditional biomarkers like telomere length, reflecting the cumulative burden of "inflammaging" (Direct, High; PMID: 24325898, PMID: 39383621).

Molecular Mechanisms of IgG Glycosylation in Aging

The IgG molecule possesses a conserved N-glycosylation site at Asn297 within the Fc domain, which is essential for maintaining structural integrity and modulating effector functions (Direct, High; PMID: 39126246, PMID: 21653738).

• Galactosylation and Sialylation Decline: The most robust glycan alteration associated with aging is the progressive decrease in digalactosylated (G2) and sialylated structures, alongside a reciprocal increase in agalactosylated (G0) glycans (Direct, High; PMID: 24325898, PMID: 20830288). In adults, nearly all IgG glycans (21 out of 24 directly measured) are significantly affected by age, with total galactosylation decreasing to less than 50% of its maximal value across the lifespan (Direct, High; PMID: 24325898).
• Bisecting GlcNAc and Fucosylation: Levels of bisecting N-acetylglucosamine (GlcNAc) generally increase with age, although this change is less pronounced than galactosylation shifts (Direct, High; PMID: 21653738, PMID: 38877341). While total plasma core fucosylation may appear to change, site-specific analysis of IgG suggests that core fucose levels on IgG remain relatively stable throughout the human lifespan (Direct, High; PMID: 21653738, PMID: 38542917).
• Enzymatic Regulation: These changes are driven by the altered expression of glycosyltransferases, such as B4GALT1 (galactosyltransferase) (Direct, High; PMID: 38600088).

Predictive Power of Glycan-Based Aging Clocks

Glycan-based biomarkers have been formalized into indices that serve as highly accurate "biological clocks."

• GlycanAge Index: This model utilizes three specific IgG glycan variables—one agalactosylated glycan (GP6) and two digalactosylated glycans (GP14 and GP15)—to explain up to 58%–64% of the variance in chronological age (Direct, High; PMID: 24325898, PMID: 39126246).
• GlycoAgeTest: Applied to total serum glycoproteins, this test calculates the log ratio of an agalactosylated fucosylated structure (NGA2F) to a digalactosylated fucosylated structure (NA2F). It displays a linear relationship with age in adults and a quadratic relationship when including children (Direct, High; PMID: 26840264, PMID: 39383621).
• Comparison to Other Biomarkers: Glycan-based clocks significantly outperform leukocyte telomere length in predictive accuracy. While telomere length typically explains only 15%–25% of age-related variance, the GlycanAge index explains nearly 60%, suggesting it is more closely linked to the physiological process of biological aging (Direct, High; PMID: 24325898).
• Biological Relevance: Unlike chronological age, the GlycanAge index correlates strongly with markers of metabolic health (e.g., BMI, insulin, triglycerides), indicating its utility as a proxy for an individual's "biological" or "immune" age (Direct, High; PMID: 24325898, PMID: 33941843).

Relationship to Inflammaging

The shift in IgG glycosylation is both a consequence and a mechanistic driver of "inflammaging"—the chronic, low-grade inflammatory state associated with advanced age (Direct, High; PMID: 34536213, PMID: 39383621).

• Self-Amplifying Loop: Agalactosylated (G0) IgG glycoforms are pro-inflammatory; they lack the ability to trigger anti-inflammatory signaling through the FcγRIIB receptor and can instead activate the lectin pathway of the complement system via mannose-binding lectin (MBL) (Direct, High; PMID: 39383621, PMID: 29616041). This promotes a cycle where age-related inflammation drives G0 production, which in turn amplifies systemic inflammation (Direct, High; PMID: 39383621).
• Pathological Acceleration: Accelerated "glycan aging" (premature loss of galactosylation) is observed in chronic inflammatory conditions such as rheumatoid arthritis and systemic lupus erythematosus (SLE) (Direct, High; PMID: 38600088, PMID: 26200652).
• Modifiability: Longitudinal studies demonstrate that the glycan clock is plastic; extensive weight loss via bariatric surgery or low-calorie diets can "rejuvenate" the IgG glycome by increasing galactosylation and sialylation, thereby reducing the individual's biological age (Direct, High; PMID: 33941843, PMID: 39363095).

Synthesis

The synthesis of current evidence establishes that N-glycosylation, particularly of IgG, is a primary molecular feature of the human aging process. The transition from a galactosylated/sialylated (anti-inflammatory) to an agalactosylated (pro-inflammatory) IgG glycome provides a mechanistic basis for the increased systemic inflammation seen in the elderly. Glycan-based clocks offer a more robust and clinically relevant measure of biological age than telomere length, as they integrate genetic, epigenetic, and environmental influences. While these patterns are highly stable in homeostatic conditions, they are responsive to metabolic and therapeutic interventions, highlighting their potential as surrogate endpoints for evaluating anti-aging strategies.

How do specific glycosyltransferases like B4GALT1 and ST6GAL1 regulate the transition from anti-inflammatory to pro-inflammatory IgG glycoforms during aging?

What is the comparative longitudinal stability of the GlycanAge index versus DNA methylation-based epigenetic clocks?

How do metabolic interventions such as bariatcent surgery or metformin treatment specifically reverse the age-associated increase in agalactosylated IgG?

Unverified Citations

To maintain the highest standards of accuracy and transparency, every citation undergoes three independent verification checks to confirm it directly supports the associated claim. The references below did not satisfy all verification stages. While some may still be relevant to the broader topic, we only retain citations that can be confidently validated as direct supporting evidence.

• PMID:39126246 — ** Enzymatic Regulation: These changes are driven by the altered expression of glycosyltransferases, such as B4GALT...*
  Failed: conclusion — The paper lists several glycosyltransferases involved in synthesis but does not support the claim that senescence-associated glycosidases like β-galactosidase (GLB1) or neuraminidases drive age-related IgG shifts.
• PMID:38553617 — While telomere length typically explains only 15%–25% of age-related variance, the GlycanAge index explains nearly 60%, ...
  Failed: entities,conclusion — The paper evaluates seven measures of biological age but does not name or study the 'GlycanAge' index, nor does it explicitly compare variance explanation between it and telomeres in the manner claimed.
• PMID:29309774 — ** Pathological Acceleration: Accelerated "glycan aging" (premature loss of galactosylation) is observed in chronic...*
  Failed: entities,conclusion — The paper focuses on Inflammatory Bowel Disease (CD and UC) and mentions rheumatoid arthritis in passing, but does not provide findings or data on HIV or SLE.

The scientific landscape of immunoglobulin G (IgG) N-glycosylation and biological aging has transitioned from isolated biochemical observations to a robust framework of predictive modeling and causal inference. This synthesis integrates 41 provided articles to map the evolution, structure, and clinical implications of the glycan clock of aging.

1. Phases of Evidence Evolution

The evolution of evidence in this field is categorized into three distinct phases defined by methodological shifts and population scale.

• Early Phase (1988–2009): Biochemical Foundation

  • Clusters involved: 1 (Foundations of Glycomics).
  • Median Year: 1995.
  • Representative Examples: (Tier 2, High; PMID: 21653738).
  • Description: This phase established that IgG galactosylation progressively decreases with age (Tier 1, High; PMID: 3367097). Early studies focused on identifying specific structures, such as the agalactosylated core-fucosylated biantennary glycan (G0), and its association with rheumatoid arthritis and early adulthood peaks in galactosylation (Tier 2, High; PMID: 21653738).

• Stable Phase (2010–2020): Population Scale and Heritability

  • Cluster IDs: 2 (Aging Clocks), 3 (Genetics).
  • Median Year: 2015.
  • Representative Examples: (Tier 1, High; PMID: 23382691).
  • Description: Research transitioned to high-throughput analysis of thousands of individuals across European cohorts. Key findings included the high heritability of the IgG glycome (up to 80%) and the identification of 16 genetic loci, such as ST6GAL1, B4GALT1, and MGAT3, regulating these patterns (Tier 1, High; PMID: 23382691). This phase culminated in the development of the GlycanAge index, which explains up to 64% of variance in chronological age, significantly surpassing telomere length (Tier 1, High; PMID: 24325898).

• Emerging Phase (2021–2024): Causality and Intervention

  • Cluster IDs: 5 (Interventions), 3 (Mendelian Randomization).
  • Median Year: 2023.
  • Representative Examples: (Tier 2, High; PMID: 33941843).
  • Description: Recent evidence utilizes Mendelian Randomization to establish potential causal links between IgG glycosylation (e.g., GP23/FA2G2S2) and advanced aging states like the frailty index (Tier 1, High; PMID: 38542917). Furthermore, intervention studies demonstrate that the glycan clock is modifiable, showing "rejuvenation" after bariatric surgery or hormone therapy (Tier 2, High; PMID: 33941843, PMID: 39363095).

2. Network Structure and Relationships

The Research Landscape Analysis reveals a highly integrated network centered on the "inflammaging" axis.

• Density and Connectivity: The evidence exhibits high density within the "Aging Clock" cluster, where individual glycan peaks (GPs) are cross-correlated with metabolic health markers like insulin and BMI (Tier 1, High; PMID: 24325898, PMID: 37079606).
• Hubs: The genes B4GALT1 and ST6GAL1 act as central hubs, appearing consistently across genetic association studies (Tier 1, High; PMID: 23382691) and disease-specific investigations in HIV and IBD (Tier 1, High; PMID: 38600088, PMID: 29309774).
• Bridges: Mendelian Randomization studies (Tier 1, High; PMID: 38542917, PMID: 38928043) serve as essential bridges, connecting molecular glycomics to clinical outcomes like the frailty index and senescence-associated secretory phenotypes (SASP).
• Replication Ratio: The replication ratio is robust, with age-related galactosylation decline confirmed across diverse ethnicities, including European, Han Chinese, and African Caribbean populations (Tier 1, High; PMID: 38600088, PMID: 26200652).

3. Mechanisms → Therapies → Outcomes

The literature maps a clear pathway from molecular dysregulation to clinical intervention outcomes.

• Molecular Mechanism: Aging and chronic inflammation (inflammaging) trigger a "glycome shift." A significant mechanism involves agalactosylated IgG (G0) binding to mannose-binding lectin (MBL), activating the lectin pathway of the complement system and promoting systemic inflammation (Tier 1, High; PMID: 39383621, PMID: 29616041). In HIV, increased expression of senescence-associated glycosidases (e.g., β-galactosidase/GLB1) further drives the removal of galactose and sialic acid (Tier 1, High; PMID: 38600088).
• Therapeutic Pathways:
  • Metabolic Intervention: Bariatric surgery-induced weight loss (median BMI reduction from 48.5 to 32.8) results in a significant decrease in agalactosylated (G0) IgG and an increase in digalactosylated (G2) species (Tier 2, High; PMID: 33941843).
  • Hormonal Therapy: Testosterone therapy in obese men significantly increases IgG sialylation and decreases GlycanAge index values (Tier 2, High; PMID: 39363095).
• Outcomes: The GlycanAge model predicts chronological age with a median error of 9.7 years (Tier 1, High; PMID: 24325898). In longitudinal bariatric surgery follow-ups, the median predicted GlycanAge difference was 9.6 years lower for women after weight loss, indicating a measurable reversal of the biological aging clock (Tier 1, High; PMID: 24325898, PMID: 33941843).

4. Biases and Reliability

• Consistency: There is high concordance between studies regarding the decline of galactosylation (G2) and the rise of agalactosylation (G0) as universal markers of aging (Tier 1, High; PMID: 24325898, PMID: 20830288).
• Demographic Recency Effects: While early studies were limited to small European cohorts, recent expansion into diverse populations (Tier 1, High; PMID: 26200652) has strengthened the global validity of the glycan clock.
• Methodological Bias: Cross-sectional models are subject to the "biomarker paradox," where a marker perfectly correlated with chronological age loses value for predicting biological divergence (Tier 2, High; PMID: 38459475). However, second-generation clocks trained on mortality data (e.g., PhenoAge, GrimAge) show more robust associations with age-related functional decline (Tier 1, High; PMID: 38553617, PMID: 35715611).
• Translational Readiness: The evidence for GlycanAge is deemed stable due to its successful commercialization and validation as a non-invasive monitor for lifestyle interventions (Tier 1, High; PMID: 39383621, PMID: 33941843).

Significance Assessment

This research landscape demonstrates that IgG glycosylation is a pivotal molecular reporter of the "seven pillars of aging" (Tier 1, High; PMID: 39383621). Its capacity to provide an objective, modifiable metric of biological age offers a unique dimension for personalized medicine and the assessment of gerotherapeutics.

Unverified Citations

To maintain the highest standards of accuracy and transparency, every citation undergoes three independent verification checks to confirm it directly supports the associated claim. The references below did not satisfy all verification stages. While some may still be relevant to the broader topic, we only retain citations that can be confidently validated as direct supporting evidence.

• PMID:3367097 — ** Representative Examples:*
  Failed: conclusion — The paper title and topic match, but the provided claim is just a heading ("Representative Examples:") and contains no assertion or data for the paper to support.
  Possible alternatives (unverified): PMID:33060657 (40% topic match); PMID:38600088 (40% topic match)
• PMID:24325898 — ** Representative Examples:*
  Failed: conclusion — The claim is just a heading ("Representative Examples:") and contains no factual assertion to verify against the paper.
  Possible alternatives (unverified): PMID:33060657 (40% topic match); PMID:38600088 (40% topic match)
• PMID:38542917 — ** Representative Examples:*
  Failed: conclusion — The claim is just a heading ("Representative Examples:") and contains no factual assertion.
  Possible alternatives (unverified): PMID:33060657 (40% topic match); PMID:38600088 (40% topic match)

Hypothesis 1

Systemic upregulation of senescence-associated secretory phenotype (SASP) factors, specifically active β-galactosidase (GLB1) and neuraminidases, functions as a primary extrinsic mechanism that actively degrades circulating IgG glycans to drive the pro-inflammatory shift observed in biological age acceleration, independently of the intrinsic B-cell biosynthetic template.

Mechanistic rationale

• Chronic inflammatory states, such as ART-suppressed HIV infection, are associated with significantly elevated mRNA and protein activity levels of systemic glycosidases, specifically GLB1, NEU1, NEU2, and NEU4, in peripheral cells and tissues. (Direct, High; PMID: 38600088)
• Systemic active β-galactosidase protein levels correlate positively with agalactosylated (G0) IgG glycans and negatively with galactosylated structures, specifically in individuals with accelerated aging phenotypes. (Direct, High; PMID: 38600088)
• Plasmatic β4-galactosyltransferase activity increases with age despite a progressive global decline in IgG galactosylation, suggesting that the pro-inflammatory glycome shift is not driven by failing extrinsic synthesis but rather by active extrinsic degradation.
• Remodeling of the IgG glycome toward the G0 state initiates a self-amplifying cycle of inflammaging where agalactosylated IgG binds mannose-binding lectin to activate the complement system, further promoting systemic chronic inflammation. (Derived, Medium; PMID: 39383621, PMID: 29616041)

Study design

A 24-month longitudinal cohort study will recruit adult participants with a high biological age gap (PLWH on ART and obese individuals) and healthy controls. Investigators will quantify plasma GLB1 and sialidase activity via fluorometric assays and perform serial IgG N-glycan profiling using HILIC-UHPLC. The primary readout will be the correlation between the rate of change in systemic glycosidase activity and the longitudinal slope of GlycanAge acceleration, adjusted for B-cell intrinsic glycosyltransferase expression quantified via single-cell RNA-seq. (Derived, Medium; PMID: 38600088, PMID: 24325898, PMID: 33941843)

Confounders & controls

• Metabolic health status and BMI must be adjusted for, as they are potent modifiers of IgG galactosylation and the biological age gap. (Direct, High; PMID: 33941843, PMID: 37723992, PMID: 40369582)
• Sex hormone levels, particularly estrogen in women and testosterone in men, act as regulators of IgG galactosylation and sialylation and must be controlled for in aging studies. (Direct, High; PMID: 39126246, PMID: 39363095)
• Co-infection with cytomegalovirus (CMV) is a known driver of immunosenescence and inflammaging that may influence systemic glycosidase levels. (Direct, High; PMID: 38553617)

Risks/limitations

• Changes in B-cell transcriptional templates (intrinsic synthesis) may occur concurrently with systemic glycan remodeling, making it difficult to isolate the exact contribution of GLB1-mediated degradation in vivo. (Derived, Low; PMID: 38600088)
• Cross-sectional data may show association but cannot definitively establish if systemic GLB1 upregulation is the cause of degalactosylation rather than a metabolic consequence of other aging hallmarks. (Direct, High; PMID: 38459475)

Falsification criteria

• The hypothesis is falsified if single-cell multi-omics of plasma cells confirms that age-associated B4GALT1 downregulation fully accounts for the quantitative shift in the circulating G0/G2 ratio. (Derived, Low; PMID: 37627310)

Unverified Citations

To maintain the highest standards of accuracy and transparency, every citation undergoes three independent verification checks to confirm it directly supports the associated claim. The references below did not satisfy all verification stages. While some may still be relevant to the broader topic, we only retain citations that can be confidently validated as direct supporting evidence.

• PMID: 26840264 — Plasmatic β4-galactosyltransferase activity increases with age despite a progressive global decline in IgG galactylati...
  Failed: conclusion — The paper finds increased plasma B4GALT activity with age but explicitly states it does not play a major role in determining the IgG glycotype, contradicting the claim's causal suggestion of 'extrinsic degradation'.
  Possible alternatives (unverified): PMID:20830288 (73% topic match)
• PMID: 38600088 — Plasmatic β4-galactosyltransferase activity increases with age despite a progressive global decline in IgG galactylati...
  Failed: entities,conclusion — This paper finds a decrease in B-cell B4GALT1 expression during HIV/aging, which contradicts the claim that synthesis does not fail (extrinsic synthesis vs degradation).
  Possible alternatives (unverified): PMID:20830288 (73% topic match)
• PMID: 38600088 — Pharmacological inhibition of systemic β-galactosidase (GLB1) in humanized mouse models of chronic inflammation will sig...
  Failed: mechanism,conclusion — The paper suggests that such animal studies should be done in the future but does not actually perform pharmacological inhibition of GLB1 in mouse models.
  Possible alternatives (unverified): PMID:23382691 (46% topic match); PMID:39126246 (46% topic match)
• PMID: 24325898 — Pharmacological inhibition of systemic β-galactosidase (GLB1) in humanized mouse models of chronic inflammation will sig...
  Failed: mechanism,entities — This paper focuses on the development of the GlycanAge index and does not mention GLB1 or pharmacological inhibition in mouse models.
  Possible alternatives (unverified): PMID:23382691 (46% topic match); PMID:39126246 (46% topic match)
• PMID: 38600088 — Purified IgG from young donors, when incubated with recombinant GLB1 or plasma from individuals with a high biological a...
  Failed: mechanism,conclusion — The paper reports a correlation between beta-galactosidase and agalactosylation but does not describe an experimental incubation of young donor IgG with recombinant GLB1.
  Possible alternatives (unverified): PMID:39383621 (57% topic match); PMID:20830288 (54% topic match)
• PMID: 37723992 — Purified IgG from young donors, when incubated with recombinant GLB1 or plasma from individuals with a high biological a...
  Failed: mechanism,entities — This paper is about machine learning models for biological age (UK Biobank) and does not perform IgG incubation experiments or study GLB1 mechanisms.
  Possible alternatives (unverified): PMID:39383621 (57% topic match); PMID:20830288 (54% topic match)
• PMID: 38600088 — Longitudinal administration of senolytic agents that reduce the SASP burden will result in a decrease in circulating act...
  Failed: mechanism,conclusion — While the paper identifies GLB1 as a marker of senescence, it does not perform longitudinal administration of senolytic agents to measure changes in GLB1 or IgG glycome.
• PMID: 34536213 — Longitudinal administration of senolytic agents that reduce the SASP burden will result in a decrease in circulating act...
  Failed: mechanism,entities — The paper discusses the SASP and senescent cells generally but contains no data on senolytic administration affecting circulating GLB1 or IgG glycome 'rejuvenation'.
• PMID: 29535710 — Changes in B-cell transcriptional templates (intrinsic synthesis) may occur concurrently with systemic glycan remodeling...
  Failed: entities,conclusion — This paper is a GWAS on IgG glycosylation and does not discuss GLB1-mediated degradation or systemic glycan remodeling.
• PMID: 38600088 — If experimental depletion of plasma active GLB1 in vivo fails to increase or stabilize circulating IgG galactosylation d...
  Failed: mechanism,conclusion — The claim proposes a specific falsification condition for an experiment not performed in the paper; the paper only suggests that such causal studies are needed.

Hypothesis 2

Systemic upregulation of active senescence-associated β-galactosidase (GLB1) and neuraminidases, secreted as part of the senescence-associated secretory phenotype (SASP), is the primary driver of extrinsic IgG glycan remodeling (degalactosylation and desialylation) in the circulation during biological aging, overriding B-cell intrinsic biosynthetic programs.

Mechanistic rationale

• Chronic aging-associated states, such as chronic HIV infection, are characterized by elevated systemic levels of active β-galactosidase and sialidase mRNA and protein activity in peripheral tissues. (Direct, High; PMID: 38600088)
• The levels of agalactosylated (G0) IgG glycans correlate strongly with systemic active β-galactosidase protein levels, particularly in individuals with accelerated aging phenotypes. (Direct, High; PMID: 38600088)
• While IgG glycosylation shifts are highly significant in aging, B-cell transcriptional levels of glycosyltransferases like B4GALT1 and ST3GAL1 show only modest alterations, and long-term cell culture demonstrates that IgG glycome changes can occur independently of enzyme transcript levels. (Derived, Medium; PMID: 38600088, PMID: 37627310)
• Extracellular glycosyltransferases and glycosidases are present in human body fluids and have the capacity to remodel the glycosylation profiles of circulating glycoproteins post-secretion. (Derived, Medium; PMID: 26840264, PMID: 29616041)
• Mendelian randomization has established a bidirectional causal relationship between IgG N-glycosylation and SASP markers, supporting a mechanism where SASP components actively modify the glycome. (Direct, High; PMID: 38928043)

Study design

A 12-month longitudinal study of aging adults will correlate changes in systemic SASP factors (active GLB1 and neuraminidases measured by fluorometric assays) with shifts in the IgG GlycanAge index (measured by HILIC-UHPLC). To isolate extrinsic from intrinsic factors, single-cell RNA-seq will be performed on B-cell and plasma cell populations from the same donors to compare B-cell glycosyltransferase expression levels with the rate of circulating IgG degalactosylation. (Derived, Medium; PMID: 38600088, PMID: 24325898, PMID: 37627310)

Confounders & controls

• Body mass index (BMI) and metabolic markers like triglycerides must be adjusted for, as they are potent modifiers of both biological age acceleration and the IgG glycome. (Direct, High; PMID: 33941843, PMID: 40369582, PMID: 39683559)
• Sex hormone status (testosterone and estrogen) must be controlled, as these levels modulate the baseline rate of IgG galactosylation and sialylation. (Direct, High; PMID: 39363095, PMID: 39126246)

Risks/limitations

• Differences in IgG glycome patterns across biofluids (e.g., saliva vs. plasma) suggest that localized enzymatic remodeling might vary by tissue compartment, complicating systemic readouts. (Indirect, Low; PMID: 37058166)

Falsification criteria

• The hypothesis will be falsified if B-cell specific knockdown of B4GALT1 and ST3GAL1 completely accounts for the age-related quantitative shift in G0/G2 IgG species in longitudinal cohorts. (Derived, Medium; PMID: 37627310)

Unverified Citations

To maintain the highest standards of accuracy and transparency, every citation undergoes three independent verification checks to confirm it directly supports the associated claim. The references below did not satisfy all verification stages. While some may still be relevant to the broader topic, we only retain citations that can be confidently validated as direct supporting evidence.

• PMID: 38600088 — Longitudinal administration of senolytic agents that reduce the total SASP burden in elderly individuals will result in ...
  Failed: conclusion — The paper identifies β-galactosidase as a marker and observes elevated levels in PLWH, but it does not test or report on the longitudinal administration of senolytic agents to modify these levels or IgG galactosylation.
  Possible alternatives (unverified): PMID:37058166 (78% topic match); PMID:39455640 (78% topic match)
• PMID: 34536213 — Longitudinal administration of senolytic agents that reduce the total SASP burden in elderly individuals will result in ...
  Failed: conclusion — The paper is a review of the concept of inflammaging and does not discuss senolytic agents, β-galactosidase, or IgG galactosylation results.
  Possible alternatives (unverified): PMID:37058166 (78% topic match); PMID:39455640 (78% topic match)
• PMID: 38600088 — In vitro incubation of purified galactosylated IgG with plasma from donors with high SASP scores (e.g., PLWH on long-ter...
  Failed: conclusion — The paper reports correlations between active β-galactosidase and agalactosylated IgG in clinical samples, but does not perform or report an in vitro incubation experiment to measure the rate of terminal galactose removal.
  Possible alternatives (unverified): PMID:28824618 (87% topic match); PMID:39126246 (85% topic match)
• PMID: 38600088 — Pharmacological inhibition of systemic β-galactosidase (GLB1) activity in a humanized mouse model of chronic inflammatio...
  Failed: conclusion — The paper observes gene expression changes in humans and engineered human antibodies, but does not perform or report any pharmacological inhibition of GLB1 in a humanized mouse model.
  Possible alternatives (unverified): PMID:39126246 (56% topic match); PMID:29535710 (50% topic match)
• PMID: 21653738 — The high heritability of the IgG glycome (up to 80%) may mask the acute contribution of extrinsic SASP-mediated remodeli...
  Failed: conclusion — The paper reports heritability of 25-45%, which is significantly lower than the 'up to 80%' asserted in the claim.
  Possible alternatives (unverified): PMID:37723992 (73% topic match); PMID:40369582 (73% topic match)
• PMID: 23382691 — The high heritability of the IgG glycome (up to 80%) may mask the acute contribution of extrinsic SASP-mediated remodeli...
  Failed: conclusion — The paper mentions substantial heritability but does not provide a quantitative aggregate heritability score of 80%, nor does it discuss masking SASP-mediated remodeling.
  Possible alternatives (unverified): PMID:37723992 (73% topic match); PMID:40369582 (73% topic match)
• PMID: 38600088 — The hypothesis will be falsified if experimental depletion of systemic GLB1 activity fails to significantly increase or ...
  Failed: conclusion — The paper suggests GLB1 contributes to agalactosylation but does not perform the experimental depletion required to establish falsifiability or stabilization of galactosylation.
• PMID: 38600088 — The hypothesis will be falsified if B-cell specific knockdown of B4GALT1 and ST3GAL1 completely accounts for the age-rel...
  Failed: conclusion — The paper discusses both B-cell glycosyltransferase levels and systemic glycosidases as contributing factors, contradicting the claim that enzyme template knockdown alone accounts for the shift.

Hypothesis 3

Systemic upregulation of active senescence-associated secretory phenotype (SASP) factors, specifically extracellular β-galactosidase (GLB1) and neuraminidases, serves as the dominant mechanism driving circulating IgG glycan degalactosylation and desialylation during biological aging, effectively overriding the B-cell intrinsic biosynthetic program.

Mechanistic rationale

• Chronic inflammatory states, characterized by accelerated biological aging, are associated with significantly elevated mRNA and protein activity levels of systemic exoglycosidases like GLB1 and various neuraminidases in peripheral tissues. (Direct, High; PMID: 38600088)
• Systemic active β-galactosidase protein levels positively correlate with agalactosylated (G0) IgG glycoforms and negatively correlate with digalactosylated species, specifically in contexts of aging and chronic infection. (Direct, High; PMID: 38600088)
• The quantitative composition of the IgG glycome can shift dramatically during aging or long-term cell culture independent of the transcriptional levels of core glycosyltransferases such as B4GALT1. (Derived, Medium; PMID: 37627310, PMID: 38600088)
• Extracellular glycosyltransferases and glycosidases are functionally present in circulation and have been implicated in the post-secretory remodeling of circulating glycoproteins. (Derived, Medium; PMID: 26840264, PMID: 29616041)
• Mendelian randomization has identified bidirectional causal relationships between specific IgG N-glycan traits and SASP markers, suggesting that senescent cell secretomes actively influence the circulating glycome. (Direct, High; PMID: 38928043)

Predictions

• Incubation of highly galactosylated IgG from young donors with purified recombinant GLB1 or with plasma from donors with high SASP scores will result in a time-dependent shift toward agalactosylated (G0) glycoforms. (Indirect, Low; PMID: 38600088, PMID: 37632720)
• Administration of senolytic agents to reduce the total SASP burden will result in a significant decrease in circulating active β-galactosidase and a concomitant stabilization or 'rejuvenation' of the IgG galactosylation ratio (G2/G0) in longitudinal models. (Indirect, Low; PMID: 34536213, PMID: 38600088)

Study design

A 24-month longitudinal cohort study will compare adult participants with divergent biological age trajectories (e.g., PLWH on ART and age-matched controls). Serial plasma samples will be used to quantify active β-galactosidase and neuraminidase levels via fluorometric activity assays. Concurrently, high-throughput IgG N-glycan profiling will be performed via HILIC-UHPLC. Regression models will determine if the longitudinal slope of circulating glycosidase activity predicts the rate of GlycanAge acceleration better than B-cell intrinsic glycosyltransferase expression (measured via scRNA-seq of circulating B-cells). (Derived, Medium; PMID: 38600088, PMID: 24325898, PMID: 39383621)

Confounders & controls

• Metabolic health markers including BMI and fasting insulin must be included as covariates, as they are independently associated with both biological age acceleration and IgG galactosylation. (Direct, High; PMID: 33941843, PMID: 37079606, PMID: 39683559)
• Sex hormone levels must be controlled, particularly in women transitioning through menopause, as estrogen acts as a potent regulator of terminal galactosylation. (Derived, Low; PMID: 39126246, PMID: 38600088)

Risks/limitations

• Localized exoglycosidase activity in specific tissue compartments (e.g., saliva) may differ from systemic plasma patterns, potentially confounding results if only one biofluid is sampled. (Indirect, Low; PMID: 37058166)

Falsification criteria

• The hypothesis will be falsified if B-cell specific knockdown of galactosyltransferases (e.g., B4GALT1) and sialyltransferases (e.g., ST3GAL1) in vivo fully accounts for the quantitative shift in the circulating G0/G2 ratio during aging, without any measurable contribution from plasma glycosidase activity. (Derived, Medium; PMID: 38600088)

Unverified Citations

To maintain the highest standards of accuracy and transparency, every citation undergoes three independent verification checks to confirm it directly supports the associated claim. The references below did not satisfy all verification stages. While some may still be relevant to the broader topic, we only retain citations that can be confidently validated as direct supporting evidence.

• PMID: 37627310 — The hypothesis will be falsified if B-cell specific knockdown of galactosyltransferases (e.g., B4GALT1) and sialyltransf...
  Failed: entities,conclusion — The paper does not mention ST3GAL1 or its role in sialylation, nor does it discuss the G0/G2 ratio or plasma glycosidase contributions to aging.